| abstract |
A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: n n nwherein X represents a halogen or a hydrogen atom, R 1 and R 2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R 1 and R 2 , together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S, 4S)-6-fluoro-2′,5′-dioxospiro [chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea |